Abstract: This invention describes the new 11&bgr;-halogen-7&agr;-substituted estratrienes of general formula I 1

Abstract: This invention describes the new benzocycloheptenes of general formula I 1

Abstract: Benzocycloheptenes of general formula I in which R1, R2 and Y have the meanings indicated herein, have antiestrogenic activity on and are suitable for the production of pharmaceutical agents, especially for prophylaxis and therapy of osteoporosis.

Abstract: This invention describes the new benzocycloheptenes of general formula I 1

Abstract: This invention describes the new 7&agr;-(5-methylaminopentyl)-estratrienes of general formula I in which R2 stands for a hydrogen or fluorine atom, R17 stands for a hydrogen atom, a methyl or ethinyl group, n stands for 2, 3 or 4, and x stands for 0, 1 or 2. The new compounds are strong, pure antiestrogens and can be used for the production of pharmaceutical agents for treatment of estrogen-dependent diseases, for example, breast cancer, endometrial carcinoma, prostatic hyperplasia, anovulatory infertility and melanoma.

Abstract: This invention describes new, substituted 7&agr;-(&egr;-aminoalkyl)-estratrienes of general formula I in which side chain SK is a radical of partial formula The new compounds represent compounds with very strong antiestrogenic action. The compounds according to the invention are, on the one hand, pure antiestrogens, or, on the other hand, antiestrogens with estrogenic partial action. Based on this spectrum of action, the new compounds are highly suitable for the production of pharmaceutical agents for tumor therapy and hormone replacement treatment.

Abstract: This invention describes 11&bgr;-aryl-substituted 14,17-ethanoestratrienes of general formula (I). The new compounds are selective estrogens whose action occurs in a tissue-selective manner. The estrogenic action occurs in particular on bone, in the cardiovascular system and in the CNS (central nervous system). Only a slight estrogenic action or no estrogenic action occurs in the uterus and in the liver, however. The compounds are suitable for the production of pharmaceutical agents for use in numerous indications (for example for hormone replacement therapy, prevention and treatment of osteoporosis).

Abstract: This invention relates to new antiestrogens of the general formula ##STR1## in which the substituents have the meanings that are explained in more detail in the description.The new compounds are a) pure antiestrogens or b) antiestrogens with partial estrogenic action (tissue-selective estrogens).Based on these properties, the new compounds are suitable for the production of pharmaceutical agents: in the case of a), for example, for the treatment of breast cancer; in the case of b), for example, for hormone replacement therapy.

Abstract: This invention describes the new 17-difluoromethylene-estratrienes of general formula I ##STR1## in which R.sup.1 is a hydrogen atom or a C.sub.1 -C.sub.10 alkyl group,R.sup.5 is a methyl or ethyl group, andR.sup.2 is a hydrogen atom or a C.sub.1 -C.sub.10 alkyl group in .alpha.- or .beta.-position,R.sup.3 is a hydrogen atom or a C.sub.1 -C.sub.10 alkyloxy group in .alpha.- or .beta.-position,R.sup.4 is a hydrogen atom in .alpha.- or .beta.-position, and A, B, D, E and G each is a hydrogen atom, and optionally at least one of substituent pairsG and R.sup.2, R.sup.2 and R.sup.4, R.sup.4 and A, A and R.sup.3, B and D, D and E is a double bond.

Abstract: This invention describes the new 17-difluoromethylene-estratrienes of general formula I ##STR1## in which R.sup.1 means a hydrogen atom or a C.sub.1 -C.sub.10 alkyl group,R.sup.5 means a methyl or ethyl group, andR.sup.2 means a hydrogen atom or a C.sub.1 -C.sub.10 alkyl group in .alpha.- or .beta.-position,R.sup.3 means a hydrogen atom or a C.sub.1 -C.sub.10 alkyloxy group in .alpha.- or .beta.-position,R.sup.4 means a hydrogen atom in .alpha.- or .beta.-position, andA, B, D, E and G each mean a hydrogen atom, and optionally at least one of substituent pairsG and R.sup.2, R.sup.2 and R.sup.4, R.sup.4 and A, A and R.sup.3, B and D, D and E mean a double bond.

Abstract: This invention describes new, substituted 7.alpha.-(.xi.-aminoalkyl)-estratrienes of general formula I ##STR1## in which side chain SK is a radical of partial formula ##STR2## as well as their physiologically compatible addition salts with organic and inorganic acids.The new compounds represent compounds with very strong antiestrogenic action.The compounds according to the invention are, on the one hand, pure antiestrogens, or, on the other hand, antiestrogens with estrogenic partial action. Based on this spectrum of action, the new compounds are highly suitable for the production of pharmaceutical agents for tumor therapy and hormone replacement treatment.

Abstract: This invention describes new, substituted 7.alpha.-(.xi.-aminoalkyl)-estratrienes of general formula I ##STR1## in which side chain SK is a radical of partial formula ##STR2## as well as their physiologically compatible addition salts with organic and inorganic acids.The new compounds represent compounds with very strong antiestrogenic action.The compounds according to the invention are, on the one hand, pure antiestrogens, or, on the other hand, antiestrogens with estrogenic partial action. Based on this spectrum of action, the new compounds are highly suitable for the production of pharmaceutical agents for tumor therapy and hormone replacement treatment.

Abstract: This invention describes the new triphenylethylenes of general formula I ##STR1## in which n means an integer from 1 to 10,R' means a sulfur-containing organic radical,R" means a hydrogen atom, an iodine atom or a hydroxy groups,E means a hydrogen atom,G means a hydrogen atom orE and G together mean a methylene bridge.The new compounds have strong antiestrogenic properties and are suitable for the production of pharmaceutical agents, for example for treating breast cancer.

Abstract: N-fluorosulfonimides of general formula I(R.sup.1 --SO.sub.2).sub.2 NF (I),in whichR.sup.1 means a methyl group each or together a group --(CH.sub.2).sub.n --with n=1, 2 or 3, especially N-flouromethanesulfonimide, (CH.sub.3 SO.sub.2).sub.2 NF, their production as well as their use for electrophilic fluorination of activated C--H bonds of organic molecules, are described.

Abstract: The invention relates to 11 .beta.-substituted 14,17-ethanoestratrienes of the general formula 1 ##STR1## where R.sup.1, R.sup.2 and R.sup.3 are defined in the specification. The compound have antiestrogenic activity and are, therefore, useful for the treatment of estrogen dependent disorders.

Abstract: The disclosure relates to cycloalkylene azoles of general Formula I ##STR1## wherein ##STR2## is a carbocyclic or carbopolycyclic group optionally carrying at least on a alkyl substituent,X is a grouping ##STR3## an oxygen or sulfur atom, and Y and Z, independently of each other, are ##STR4## or a nitrogen atom, as well as their pharmaceutically compatible addition salts with acids as well as processes for production thereof. The compounds possess strongly aromatase-inhibiting activity and are suitable for the preparation of medicinal agents.Methods for treating estrogen induced or stimulated tumors, male infertility, and impending cardiac infarction with these compounds are also provided as well as methods for inhibiting female fertility.

Abstract: Pharmaceutical preparations comprising functionalized vinyl azoles of formula I ##STR1## wherein the substituents are as defined herein, including novel compounds, as well as methods of use and methods of their preparation, are provided.

Abstract: The disclosure relates to cycloalkylene azoles of general Formula I ##STR1## wherein ##STR2## is a carbocyclic or carbopolycyclic group optionally carrying at least one alkyl substituent,is the grouping ##STR3## an oxygen or sulfur atom, and Y and Z, independently of each other, are ##STR4## or a nitrogen atom, as well as their pharmaceutically compatible addition salts with acids as well as processes for production thereof. The compounds possess strongly aromatase-inhibiting activity and are suitable for the preparation of medicinal agents.Methods for treating estrogen induced or stimulated tumors, male infertility, and impending cardiac infarction with these compounds are also provided as well as methods for inhbiiting female fertility.

Abstract: Disclosed are novel 14,17.alpha.-etheno- and -ethanoestratrienes according to general Formula I ##STR1## wherein X is a --CH.sub.2 --CH.sub.2 or ##STR2## R.sup.1 is a hydrogen atom, a C.sub.1 - to C.sub.15 -acyl, benzoyl, C.sub.1 - to C.sub.15 -alkyl, C.sub.3 - to C.sub.9 -cycloalkyl or alkylcycloalkyl group, andR.sup.2 is the grouping ##STR3## wherein R.sup.3 and R.sup.4 independently of each other mean a hydrogen atom or a straight-chain or branched, optionally partially or completely fluorinated C.sub.1 -C.sub.8 -alkyl group,a process for their preparation, pharmaceutical preparations containing these compounds, as well as their use for the production of medicinal agents.The novel compounds exhibit strong antiestrogenic efficacy.

Abstract: The disclosure relates to cycloalkylene azoles of general Formula I ##STR1## wherein ##STR2## is a carbocyclic or carbopolycyclic group optionally carrying at least one alkyl substituent,X is the grouping ##STR3## an oxygen or sulfur atom, and Y and Z, independently of each other, are ##STR4## or a nitrogen atom, as well as their pharmaceutically compatible addition salts with acids as well as processes for production thereof. The compounds possess strongly aromatase-inhibiting activity and are suitable for the preparation of medicinal agents.Methods for treating estrogen induced or stimulated tumors, male infertility, and impending cardiac infarction with these compounds are also provided as well as methods for inhibiting female fertility.